The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Recent FDA approval of exa-cel & lovo-cel for patients with SCD
Akshat Jain, MD, MPH, FRCP, Loma Linda University, San Bernadino, CA, shares insights into the exciting recent FDA approval of two gene therapies, lovotibeglogene autotemcel (lovo-cel) and exagamglogene autotemcel (exa-cel), for patients with sickle cell disease (SCD). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
